

Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes

Lars C. Hanker · Achim Rody · Uwe Holtrich · Lajos Pusztai ·
Eugen Ruckhaeberle · Cornelia Liedtke · Andre Ahr ·
Tomas M. Heinrich · Nicole Sanger · Sven Becker · Thomas Karn

Received: 16 November 2012 / Accepted: 22 November 2012
© Springer Science+Business Media New York 2012

Abstract We recently reported that a ratio of high B cell and low IL-8 metagene expression identified 32 % of triple negative breast cancers (TNBC) with good prognosis and was the only significant predictor in multivariate analysis including routine clinicopathological variables. However, the clinical relevance of this signature in other breast cancer subtypes remains unclear. We compiled Affymetrix gene expression datasets from 4,467 primary breast cancer samples and excluded 329 triple negative samples which were used as discovery cohort in our previous study. Molecular classification of the remaining 4,138 samples

was performed by two methods, including single genes (ER, PgR, HER2, and Ki67) and a centroid-based method using the intrinsic gene list. The prognostic value within the respective subtypes was assessed by analyzing the event-free survival of patients as a function of the B cell/IL-8 metagene ratio using previously published cutoff. ER-negative subtypes had the highest expression of the B cell and the IL-8 metagenes. The IL-8/B cell signature assigned a considerable fraction of samples (range 20.7–42.0 %) into the “*good prognosis*” group. However, a significant prognostic value was only observed in the subgroup of triple negative breast cancer ($P = 0.035$). The prognostic value of the B cell/IL-8 ratio is mainly confined to the basal-like and TNBC subtypes of breast cancer. This result underlines the importance of subtype-specific analyses and suggests a sequential multistep approach to developing and applying outcome predictors in the clinic.

Lars C. Hanker and Achim Rody contributed equally to this study.

Electronic supplementary material The online version of this article (doi:10.1007/s10549-012-2356-2) contains supplementary material, which is available to authorized users.

L. C. Hanker · A. Rody
Department of Gynecology and Obstetrics, University Medical
Center Schleswig-Holstein, Campus Lubeck,
Ratzeburger Allee 160, 23538 Lubeck, Germany

U. Holtrich · E. Ruckhaeberle · A. Ahr ·
T. M. Heinrich · N. Sanger · S. Becker · T. Karn (✉)
Department of Gynecology and Obstetrics, J.W. Goethe
University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
e-mail: t.karn@em.uni-frankfurt.de

L. Pusztai
Yale Cancer Center, Yale School of Medicine, 333 Cedar Street,
PO Box 208032, New Haven, CT 05620, USA

C. Liedtke
Department of Gynecology and Obstetrics, University
of Muenster, Munster, Germany

Keywords Triple negative breast cancer · Subtypes of breast cancer · Prognostic gene signature

Abbreviations

BLBC	Basal-like breast cancer
DMFS	Distant metastasis free survival
EFS	Event free survival
ER	Estrogen receptor
FNA	Fine needle aspiration
HER2	Human epidermal growth factor receptor 2
HR	Hazard ratio
IL	Interleukine
PgR	Progesterone receptor
REMARK	Recommendations for prognostic and tumor marker studies
RFS	Relapse free survival
TNBC	Triple negative breast cancer

Introduction

Breast cancer is a heterogeneous disease of different molecular subtypes. Currently, the most simple and applicable stratification of breast cancer is based on expression of the hormone receptors for both estrogen (ER) and progesterone (PgR) as well as the human epidermal growth factor receptor 2 (HER2) [36]. Based on these three receptors, tumors are characterized as hormone receptor positive, HER2 positive (i.e., amplification or overexpression of HER2), or triple negative breast cancer (TNBC) lacking the expression of all three receptors. In addition, several refined stratifications applying genomic methods or the inclusion of additional immunohistochemical markers (e.g., Ki67) allow the distinction of “Basal-like” breast cancers as well as “Luminal A” and “Luminal B” subgroups each with different prognosis and clinical behavior [27–29]. In recent years, it became increasingly clear that the subtype composition of a dataset can strongly influence the prognostic and predictive gene signatures derived from it [36, 39]. Often these “first generation” signatures represent a surrogate marker for the subtype distinction itself [29]. As a consequence, several recent guidelines have suggested to analyze subtypes of breast cancers separately and to derive subtype-specific genomic tests [12, 19].

In previous work, we had assembled a large dataset of TNBC and used an unsupervised method to derive signatures which are capable of delivering highly significant prognostic information within the TNBC subgroup [31]. In the present study, we analyzed whether this signature has also prognostic value within other subtypes of breast cancer. Interestingly, we could demonstrate that despite the signature identified similar fractions of samples among the different subtypes its prognostic significance was restricted to triple negative and basal-like breast cancer. Our results underline the importance of subtype-specific analyses and suggest a sequential multistep approach for application of future genomic tests in the clinic.

Methods

All analyses were performed according to the “*REporting recommendations for tumour MARKer prognostic studies*” (REMARK) [24, 35] and the respective guidelines to microarray-based studies for clinical outcomes [7]. A diagram of the complete analytical strategy and the flow of patients through the study, including the number of patients included in each stage of the analysis, is given in Fig. 1. We compiled Affymetrix gene expression data (U133A or U133Plus2.0 arrays) of 4,467 breast cancer patients from 40 publicly available datasets (Supplementary Table S1). However, 329 triple negative cases of these 4,467 samples

have been used before as a finding cohort in our previous studies [17, 31]. Thus, these samples had to be excluded from all subsequent analyses resulting in 4,138 applicable samples. Affymetrix CEL files were processed with the MAS5.0 algorithm of the *affy* package [9] of the Bioconductor software project [10]. Data from each array were \log_2 -transformed, median-centered, and the expression values of all the probesets from the U133A array were multiplied by a scale factor *S* so that the magnitude (sum of the squares of the values) equals one.

To identify the intrinsic subtypes of breast cancer, we used two alternative previously described approaches: First, we used the simple method according to Hugh et al. [14] which is based on the expression of single marker genes (ESR1, PgR, HER2, and Ki67) to define TNBC-, HER2-, Luminal A-, and Luminal B-subtypes. The cutoff values for ESR1, PgR, and HER2 have been described previously [16]. For a distinction of Luminal A and Luminal B subgroups, all 2,884 ERpositive/HER2negative samples were selected and a median split according to Ki67 expression was performed. In addition, 106 ERpositive/HER2positive cases were assigned to the Luminal B subtype according to Hugh et al. [14]. As a second, alternative method for subtype determination, we applied a single sample predictor (SSP) [38] according to the centroid method using the gene set from Hu et al. [13]. The centroid analyses were performed separately in six larger datasets encompassing a total of 1,142 samples. However, 195 of those samples were used as finding cohort of triple negative cases in our previous studies [17, 31] and thus had to be excluded from further analyses presented here. This exclusion results in a reduced proportion of basal-like tumors among the remaining cohort of 947 samples (see Table 1). The individual assignments according to the two different methods of molecular subtype definition are given for each sample in Supplementary Table S2.

We have previously reported an unsupervised analysis identifying metagenes that distinguish molecular subsets within TNBC [31]. In the present study, we calculated expression values for two of these metagenes, namely the B cell and IL8 metagenes, for all 4,467 samples as the mean expression of four (IL8 metagene) and 48 (B cell metagene) Affymetrix probesets, respectively. The probesets used are listed in Supplementary Table S3. We had also reported in our previous study that high expression of the B cell metagene was associated with good prognosis and high expression of the IL-8-related metagene with poor prognosis in TNBC. We had then combined the two metagenes in the previous study into a signature: Samples with both high B cell metagene and low IL-8 metagene expression were characterized as “*Good Prognosis*”; all the other samples were characterized as “*Poor Prognosis*.” The respective cutoff values (B cell metagene >0.005 and IL-8




Fig. 1 Diagram of the analytical strategy according to REMARK criteria. The analytical strategy and the flow of patients through the study is presented as recommended by the REMARK criteria [14]

metagene < -0.001) were defined in a discovery cohort of 394 TNBC [31]. In the present study, we now used these pre-defined cutoff values to assess the prognostic value of the B Cell/IL-8 signature within different molecular subtypes (see Supplementary Table S2 for the assignment of each individual sample). We then analyzed the event-free survival of patients according to this signature separately in the different molecular subtypes.

In the conduct of the presented analysis, event-free survival (EFS) was calculated as preferentially corresponding to the RFS endpoint, but measured with respect to the DMFS endpoint if RFS was not available. All results from survival analyses were verified by examining the effect of the different endpoints in stratified analyses. Followup data for those women in whom the envisaged endpoint was not reached were censored as of the last followup date or at 120 months. Subjects with missing values were excluded from the analyses. We constructed Kaplan–Meier curves and used the log-rank test to determine the univariate significance of the variables. A Cox proportional-hazards model was used to simultaneously examine the

effects of multiple covariates on survival. The effect of each individual variable was assessed with the use of the Wald test and described by the hazard ratio with a 95 percent confidence interval (95 % CI).

Results

Compilation of Affymetrix microarray datasets

Figure 1 presents the analytical strategy and the flow of patients through the study. We compiled Affymetrix gene expression data of 4,467 breast cancer patients from 40 publicly available datasets (see Methods section and Supplementary Table S1). 329 triple negative cases of these samples had to be excluded since they were used in our previous studies as a finding cohort [17, 31] leaving 4,138 applicable samples for the analyses. Table 1 gives the clinical characteristics of all 4,467 samples and of the cohort of 4,138 samples used in the subsequent analyses.

Table 1 Clinical characteristics of the samples compiled and those used in the study

Parameter	Stratification	All samples (n = 4,467)	%	Without finding cohort (n = 4,138) ^a	%
Age	>50	1,908	61.1	1,787	62.1
	≤50	1,217	38.9	1,091	37.9
Tumor size	≤2 cm	358	20.3	322	19.9
	>2 cm	1,403	79.7	1,296	80.1
Lymph node	LNN	2,040	62.5	1,843	61.0
	N+	1,225	37.5	1,177	39.0
ER	Positive	2,990	66.9	2,990	72.3
	Negative	1,477	33.1	1,148	27.7
PgR	Positive	2,466	55.2	2,466	59.6
	Negative	2,001	44.8	1,672	40.4
HER2	Positive	589	13.2	589	14.2
	Negative	3,878	86.8	3,549	85.8
Histol. grade	G3	1,524	49.2	1,341	47.0
	G1 and G2	1,575	50.8	1,510	53.0
Adjuvant treatment	No adjuvant treatment	1,108	38.3	924	34.6
	Endocrine treatment	1,182	40.8	1,166	43.7
	Chemotherapy	604	20.9	578	21.7
Follow up data available		2,590	58.0	2,353	56.9
Molecular subtype according to Hugh et al.	HER2	381	8.5	381	9.2
	Luminal A	1,442	32.3	1,442	34.8
Molecular subtype centroid method	Luminal B	1,548	34.7	1,548	37.4
	TNBC	1,096	24.5	767	18.5
	Basal-like	298	26.1	126	13.3
	HER2-like	113	9.9	110	11.6
	Luminal A	362	31.7	361	38.1
	Luminal B	200	17.5	200	21.1
	Normal-like	169	14.8	150	15.8

^a 329 TNBC cases were excluded from the cohort for all subsequent analyses since they were used as finding cohort in our previously published reports. This exclusion lowers the relative proportion of the TNBC (18.5 %) and basal-like (13.3 %) subtypes in the cohort as compared to other studies

Both B cell and IL-8 metagenes display highest expression in ER negative breast cancers

We first compared the expression of B cell and IL-8 metagenes among the different molecular subtypes of breast cancer. Molecular subtyping was performed by two alternative strategies as described in the Methods section: Either a single marker method according to Hugh et al. [14] or the centroid method applying a single sample predictor (SSP) [13, 38]. Results of the single marker method were available for all 4,138 samples: data from the centroid method for 947 cases. When the single marker method was used for stratification, we detected the lowest expression of both metagenes among the ER-positive Luminal subtypes, whereas high expression was observed in the ER negative subtypes, i.e., TNBC and HER2 (Fig. 2a, c). Similarly, when applying the centroid method for stratification, we detected the highest levels of

both the IL-8 metagene and the B cell metagene in the basal-like subgroup (Fig. 2b, d). Again, the lowest expression of both metagenes was seen in the Luminal A and Luminal B subgroups (Fig. 2b, d).

Prognostic value of the IL-8/B cell signature depends on the ER status of the tumor

Since both B cell and IL-8 metagenes displayed higher expression in ER-negative disease, we next analyzed the prognostic value of the combined IL-8/B cell signature relation to the ER status of the tumor. The previously defined cutoff values were used to stratify patients in a “good prognosis group” characterized by both high B cell and low IL-8 expression and a “poor prognosis group” encompassing all the remaining samples. Followup information was available for 2,353 samples. 28.9 and 33.5 % of the samples were assigned a “good prognosis” in the

ER-positive and ER-negative subgroup, respectively. This roughly similar relative proportion (about one third) of good prognosis samples in both ER-positive and ER-negative disease results from the reduced expression of both of the metagenes among ER-positive tumors (see Fig. 2). However, as shown in Fig. 3, the prognostic value of the signature is clearly dependent on ER status. We observed no prognostic value among ER-positive tumors ($P = 0.36$), while it was highly significant for ER negative disease ($P = 0.039$).

Prognostic value of the IL-8/B cell signature in the different molecular subtypes of breast cancer

For a more detailed analysis, we further stratified the samples according to the molecular subtypes of breast cancer. Again, we alternatively applied the two different methodologies for subtyping as given above. As shown in Table 2, in all subgroups, a considerable fraction of the samples (range 20.7–42.0 %) was assigned to “good prognosis” by the IL-8/B cell signature. We then analyzed the followup of

Fig. 2 Box plots of IL-8 and B cell metagene expression among different molecular subtypes of breast cancer. Expression of the IL-8 metagene is shown in panels (a) and (b), while expression of the B cell metagene is shown in panels (c) and (d). In a and c 4,138 breast cancer samples were stratified into molecular subtypes using single marker genes according to the method of Hugh et al. [14]. In panels b and d, a single subtype predictor (SSP) applying the centroid method was used to classify 947 samples from six larger dataset






Fig. 3 Prognostic value of the IL-8/B cell signature in ER-positive and ER-negative breast cancer. For 2,353 of the 4,138 samples, followup information was available (Table 1). The IL-8/B cell signatures were used to classify those samples into “good prognosis”

or “poor prognosis.” Kaplan–Meier analyses of the samples are shown separately for 1,941 ER-positive samples in (a) and 412 ER-negative samples in (b). A significant difference in survival was only observed in the ER negative subgroup ($P = 0.039$)

Table 2 Frequency of samples with poor/good prognosis according to the IL-8/B cell signature among the molecular subtypes of breast cancer

Subtype according to Hugh et al. [14] (n = 4,138)				Subtype according to centroid method (n = 947)			
Subtype	IL-8/B cell signature		Total	Subtype	IL-8/B cell signature		Total
	Poor prognosis	Good prognosis			Poor prognosis	Good prognosis	
TNBC	608 (79.3 %)	159 (20.7 %)	767	Basal-like	75 (59.5 %)	51 (40.5 %)	126
HER2	261 (68.5 %)	120 (31.5 %)	381	HER2-like	69 (62.7 %)	41 (37.3 %)	110
Luminal A	1,065 (73.9 %)	377 (26.1 %)	1,442	Luminal A	250 (69.3 %)	111 (30.7 %)	361
Luminal B	1,147 (74.1 %)	401 (25.9 %)	1,548	Luminal B	150 (75.0 %)	50 (25.0 %)	200
				Normal-like	87 (58.0 %)	63 (42.0 %)	150
Total	3,081 (74.5 %)	1,057 (25.5 %)	4,138	Total	631 (66.6 %)	316 (33.4 %)	947

Fig. 4 Prognostic value of the IL-8/B cell signature in different molecular subtypes of breast cancer according to the single marker method. The IL-8/B cell signature was used to classify 2,353 samples with followup information as “good prognosis” or “poor prognosis.” Separate Kaplan–Meier analyses are given in panels **a–d** for the four different subtypes of breast cancer stratified applying the single marker method. A significant prognostic value of the IL-8/B cell signature was only observed among triple negative breast cancers (panel **a**, $P = 0.035$)



the patients separately for the different subtypes. As demonstrated in Figs. 4 and 5, a significant prognostic value of the IL8/B cell signature was only observed in the TNBC subgroup ($P = 0.035$, Fig. 4a) and a strong trend in the Basal-like subtype ($P = 0.061$, Fig. 5a), respectively. Among all other subtypes, the IL-8/B cell signature displayed no significant prognostic value (Table 3).

Multivariate analysis of the prognostic value of the IL-8/B cell signature in TNBC


For 148 new TNBC samples that were not included in the finding cohort of our previous publication, both followup data and complete clinical information on lymph node

status, tumor size, age, and histologic grading were available. Table 4 displays the results of a multivariate Cox regression including all these clinical parameters together with the IL-8/B cell signature. Only the IL-8/B cell signature was significant (HR 3.20, 95 % CI 1.43–7.16; $P = 0.005$) in that analysis.

Discussion

Triple negative breast cancers (TNBC) are clinically heterogeneous and prognostic markers, and biology-based therapies are needed to better treat this disease [4, 8]. By applying a subtype-specific approach, we have previously

Fig. 5 Prognostic value of the IL-8/B cell signature in different molecular subtypes of breast cancer according to the centroid method. A single subtype predictor (SSP) applying the centroid method was used to classify 947 samples from six larger dataset into the molecular subtypes. For 787 of these samples followup information was available. Panels **a–e** show separate Kaplan–Meier analyses for the different molecular subtypes classified by the IL-8/B cell signature. A strong trend for significant difference was only observed in the Basal-like subtype ($P = 0.061$), while no prognostic value was detected in the remaining subtypes



identified a gene signature which demonstrates significant prognostic value within this subgroup of breast cancers [31]. In our current study, we show that this signature assigns similar proportions of samples to “good” or “poor” prognosis even among other subtypes of breast cancer. However, we failed to detect any significant prognostic value of the signature in subtypes other than TNBC or basal-like breast cancer. These results demonstrate the importance of subtype-specific analyses both for the development and for the application of gene signatures in a clinical setting.

Regarding the cellular source of expression of the gene signature, we had already demonstrated that lymphocyte

infiltration is responsible for the high level of expression of the B cell metagene [3, 30, 32], while IL-8 is expressed by the carcinoma cells themselves [31]. Supplementary Figure S1 displays the analyses of Affymetrix microarray data including microdissected samples which are in line with our previous results. So far, we could only demonstrate a pure prognostic value of our signature since better prognosis was observed both for patients treated with chemotherapy as well as those without adjuvant treatment [31]. We detected only a modest predictive value of the B cell metagene for response to neoadjuvant chemotherapy in our datasets [17, 31], despite that an independent larger study clearly demonstrated a predictive value of lymphocyte

Table 3 Prognostic value of the IL-8/B cell signature in different molecular subtypes of breast cancer

Subtype according to Hugh et al.	Samples with follow up	<i>P</i> value	Centroid method	Samples with follow up	<i>P</i> value
TNBC	236	0.035	Basal-like	126	0.061
HER2	176	0.40	HER2-like	108	0.48
LumA	1,052	0.63	Luminal A	356	0.87
LumB	889	0.14	Luminal B	197	0.28
			Normal-like	149	0.71
Total	2,353			936	

Table 4 Multivariate cox regression of clinical parameters and the IL-8/B cell signature in TNBC

Parameter	Numbers ^a	HR	95 % CI	<i>P</i> value ^b
IL-8/B cell signature ("Poor" vs. "Good")	103 vs. 45	3.20	1.43–7.16	0.005
Lymph node status (N + vs. LNN)	54 vs. 94	1.77	0.97–3.24	0.064
Age (>50 vs. ≤50)	84 vs. 64	1.40	0.76–2.54	0.28
Tumor size (≤1 vs. >1 cm)	26 vs. 122	0.86	0.37–2.0	0.86
Histologic grading (G3 vs. G1&G2)	106 vs. 42	1.60	0.83–3.1	0.16

^a For 148 samples of the 767 TNBC samples that were not included in the discovery cohort, both follow up data and information on all five parameters was available

^b Significant *P*-values are given in bold

infiltration within the TNBC subgroup [6]. Several recent studies suggest that the IL-8/B cell gene signature could potentially provide predictive value for specific therapeutic approaches. Inhibition of IL-8 signaling has been suggested as a target to block breast cancer stem cells and cancer's inflammatory roots [11, 20–22]. Consequentially, those TNBC patients characterized by high IL-8 expression and a poor prognosis would be first candidates for such an approach. On the other hand, T cell immunomodulators like anti-CTLA4 antibodies have shown great successes in some cancer patients at least in combination therapy [25, 33]. In this approach, it will be crucial to identify the right patients where one should take of the lid from immunosuppression [18, 26, 40] and a potential predictive value of the IL-8/B cell ratio could be worth testing.

Conclusions

A restriction of the prognostic value of different gene signatures and biologic processes to specific subtypes has been shown in many studies [2, 15, 23, 28, 29, 39]. For example, signatures consisting mainly of proliferation genes achieve their prognostic value only within ER-positive breast cancer. These subtype differences seem also to hold true for the next generation of genomic methods. Recent results from whole genome sequencing studies in breast cancer revealed that the number of somatic mutations varied markedly between individual tumors and the

number of genes which were repeatedly found to be mutated at high frequency in is rather small [34, 37]. However, the frequency of mutations clearly differs between subtypes with TNBC and HER2-positive subtypes showing higher numbers of mutations than Luminal subtypes [1]. In addition, large scale integrated analyses of copy number variation and gene expression also suggest additional molecular stratification of breast cancer beyond the known intrinsic subtypes [5]. All these data underline the importance of stratified analyses in different subtypes and suggest a sequential multistep approach for application of future genomic tests in the clinic.

Acknowledgments We thank Katherina Brinkmann and Samira Adel for expert technical assistance. This work was supported by grants from the the H.W. & J. Hector-Stiftung, Mannheim; the Margarete Bonifer-Stiftung, Bad Soden; and the BANSS-Stiftung, Biedenkopf.

Conflict of interest The authors declare that they have no conflict of interests.

References

1. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Auclair D, Bautista-Piña V, Duke F, Francis J, Jung J, Maffuz-Aziz A, Onofrio RC, Parkin M, Pho NH, Quintanar-Jurado V,

- Ramos AH, Rebollar-Vega R, Rodriguez-Cuevas S, Romero-Cordoba SL, Schumacher SE, Stransky N, Thompson KM, Uribe-Figueroa L, Baselga J, Beroukhi R, Polyak K, Sgroi DC, Richardson AL, Jimenez-Sanchez G, Lander ES, Gabriel SB, Garraway LA, Golub TR, Melendez-Zajgla J, Toker A, Getz G, Hidalgo-Miranda A, Meyerson M (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. *Nature* 486(7403):405–409
2. Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WF, Gianni L, Pusztai L (2010) Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. *Cancer Res* 70(21):8852–8862
 3. Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L (2010) Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. *J Clin Oncol* 28(28):4316–4323
 4. Carey L, Winer E, Viale G, Cameron D, Gianni L (2010) Triple-negative breast cancer: disease entity or title of convenience? *Nat Rev Clin Oncol* 7(12):683–692
 5. Curtis C, Shah SP, Chin S, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Caldas C, Aparicio S, Brenton JD, Ellis I, Huntsman D, Pinder S, Puroshotham A, Murphy L, Bardwell H, Ding Z, Jones L, Liu B, Papatheodorou I, Sammut SJ, Wishart G, Chia S, Gelmon K, Speers C, Watson P, Blamey R, Green A, Macmillan D, Rakha E, Gillett C, Grigoriadis A, Di Rinaldis E, Tutt A, Parisien M, Troup S, Chan D, Fielding C, Maia A, McGuire S, Osborne M, Sayalero SM, Spiteri I, Hadfield J, Bell L, Chow K, Gale N, Kovalik M, Ng Y, Prentice L, Tavaré S, Markowitz F, Langerød A, Provenzano E, Børresen-Dale A (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* 486(7403):346–352
 6. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hansch C, von Tonne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. *J Clin Oncol* 28:105–113
 7. Dupuy A, Simon RM (2007) Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. *J Natl Cancer Inst* 99:147–157
 8. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. *N Engl J Med* 363(20):1938–1948
 9. Gautier L, Cope L, Bolstad BM, Irizarry RA (2004) Affy-analysis of affymetrix genechip data at the probe level. *Bioinformatics* 20(3):307–315
 10. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Duodoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JYH, Zhang J (2004) Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol* 5(10):R80
 11. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum D, Guan JL, Dontu G, Wicha MS (2010) CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. *J Clin Invest* 120:485–497
 12. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn H (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer. *Ann Oncol* 22(8):1736–1747
 13. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, La Carey, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS (2006) The molecular portraits of breast tumors are conserved across microarray platforms. *BMC Genomics* 7:96
 14. Hugh J, Hanson J, Cheang MCU, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, Magherini E, Mackey J, Martin M, Vogel C (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. *J Clin Oncol* 27(8):1168–1176
 15. Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Shiang CY, Santarpia L, Matsuoka J, Hortobagyi GN, Symmans WF, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen J, Andre F, Simon R, Pusztai L (2011) Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. *J Natl Cancer Inst* 103(3):264–272
 16. Karn T, Metzler D, Ruckhäberle E, Hanker L, Gätje R, Solbach C, Ahr A, Schmidt M, Holtrich U, Kaufmann M, Rody A (2010) Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer. *Breast Cancer Res Treat* 120(3):567–579
 17. Karn T, Pusztai L, Holtrich U, Iwamoto T, Shiang CY, Schmidt M, Müller V, Solbach C, Gaetje R, Hanker L, Ahr A, Liedtke C, Ruckhäberle E, Kaufmann M, Rody A, Ranganathan S (2011) Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. *PLoS ONE* 6(12):e28403
 18. Karn T, Pusztai L, Ruckhäberle E, Liedtke C, Müller V, Schmidt M, Metzler D, Wang J, Coombes KR, Gätje R, Hanker L, Solbach C, Ahr A, Holtrich U, Rody A, Kaufmann M (2012) Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. *Eur J Cancer* 48(1):12–23
 19. Kaufmann M, Pusztai L (2011) Use of standard markers and incorporation of molecular markers into breast cancer therapy: consensus recommendations from an international expert panel. *Cancer* 117(8):1575–1582
 20. Korkaya H, Liu S, Wicha MS (2011) Breast cancer stem cells, cytokine networks, and the tumor microenvironment. *J Clin Invest* 121(10):3804–3809
 21. Korkaya H, Liu S, Wicha MS (2011) Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots. *Clin Cancer Res* 17(19):6125–6129
 22. Liu S, Wicha MS (2010) Targeting breast cancer stem cells. *J Clin Oncol* 28:4006–4012
 23. Loi S, Haibe-Kains B, Majaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt ANJ, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C (2010) PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. *Proc Natl Acad Sci USA* 107(22):10208–10213
 24. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics (2005) Reporting recommendations for tumor marker prognostic studies. *J Clin Oncol* 23:9067–9072
 25. Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. *Nature* 480(7378):480–489
 26. Ogino S, Galon J, Fuchs CS, Dranoff G (2011) Cancer immunology—analysis of host and tumor factors for personalized medicine. *Nat Rev Clin Oncol* 8(12):711–719
 27. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen La, Fluge O,

- Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. *Nature* 406:747–752
28. Prat A, Ellis MJ, Perou CM (2011) Practical implications of gene-expression-based assays for breast oncologists. *Nat Rev Clin Oncol* 9(1):48–57
29. Reis-Filho JS, Pusztai L (2011) Gene expression profiling in breast cancer: classification, prognostication, and prediction. *Lancet* 378(9805):1812–1823
30. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hankaer L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M (2009) T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. *Breast Cancer Res* 11(2):R15
31. Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hankaer L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Müller V, Holtrich U, Kaufmann M (2011) A clinically relevant gene signature in triple negative and basal-like breast cancer. *Breast Cancer Res* 13(5):R97
32. Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Boehm D, Gebhard S, Petry I, Lebrecht A, Cadenas C, Marchan R, Stewart JD, Solbach C, Holmberg L, Edlund K, Kultima HG, Rody A, Berglund A, Lambe M, Isaksson A, Botling J, Karn T, Müller V, Gerhold-Ay A, Cotarelo C, Sebastian M, Kronenwett R, Bojar H, Lehr H, Sahin U, Koelbl H, Gehrmann M, Micke P, Rahnenführer J, Hengstler JG (2012) A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. *Clin Cancer Res* 18(9):2695–2703
33. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. *Science* 331(6024):1565–1570
34. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattri J, Burleigh A, Yap D, Bernard V, McPherson A, Shumansky K, Crisan A, Giuliany R, Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan SK, Griffith M, Moradian A, Cheng SG, Morin GB, Watson P, Gelmon K, Chia S, Chin S, Curtis C, Rueda OM, Pharoah PD, Damaraju S, Mackey J, Hoon K, Harkins T, Tadigotla V, Sigaroudinia M, Gascard P, Tlsty T, Costello JF, Meyer IM, Eaves CJ, Wasserman WW, Jones S, Huntsman D, Hirst M, Caldas C, Marra MA, Aparicio S (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. *Nature* 486(7403):395–399
35. Simon RM, Paik S, Hayes DF (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. *J Natl Cancer Inst* 101(21):1446–1452
36. Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. *N Engl J Med* 360(8):790–800
37. Stephens PJ, Tarpey PS, Davies H, van Loo P, Greenman C, Wedge DC, Zainal SN, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, Cheverton A, Gamble J, Hinton J, Jia M, Jayakumar A, Jones D, Latimer C, Lau KW, McLaren S, McBride DJ, Menzies A, Mudie L, Raine K, Rad R, Spencer Chapman M, Teague J, Easton D, Langerød A, OSBREAC, Lee MTM, Shen C, Tee BTK, Huimin BW, Broeks A, Vargas AC, Turashvili G, Martens J, Fatima A, Miron P, Chin S, Thomas G, Boyault S, Mariani O, Lakhani SR, van de Vijver M, van 't Veer L, Foekens J, Desmedt C, Sotiriou C, Tutt A, Caldas C, Reis-Filho JS, Aparicio SAJR, Salomon AV, Børresen-Dale A, Richardson A, Campbell PJ, Futreal PA, Stratton MR, Karsen R, Schlichting E, Naume B, Sauer T, Ottestad L (2012) The landscape of cancer genes and mutational processes in breast cancer. *Nature* 486(7403):400–404
38. Weigelt B, Mackay A, A'Hern R, Natrajan R, Tan DSP, Dowsett M, Ashworth A, Reis-Filho JS (2010) Breast cancer molecular profiling with single sample predictors: a retrospective analysis. *Lancet Oncol* 11(4):339–349
39. Weigelt B, Pusztai L, Ashworth A, Reis-Filho JS (2011) Challenges translating breast cancer gene signatures into the clinic. *Nat Rev Clin Oncol* 9(1):58–64
40. Zitvogel L, Kepp O, Kroemer G (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. *Nat Rev Clin Oncol* 8(3):151–160